iris neovascularization
Showing 1 - 25 of 618
Neovascular Glaucoma, Neovascularization Trial in Guangzhou (4mg/ml KDR2-2 suspension eyedrop, 16mg/ml KDR2-2 suspension
Recruiting
- Neovascular Glaucoma
- Neovascularization
- 4mg/ml KDR2-2 suspension eyedrop
- 16mg/ml KDR2-2 suspension eyedrop
-
Guangzhou, Guangdong, ChinaZhongshan Ophthalmic Center
Jan 4, 2022
Neovascular Glaucoma Trial in Aurora (Aflibercept)
Completed
- Neovascular Glaucoma
-
Aurora, ColoradoRocky Mountain Lions Eye Institute
Feb 16, 2022
Non Proliferative Diabetic Retinopathy(NPDR) Trial in Tianjin (pars plana vitrectomy(PPV), Pars plana vitrectomy(PPV)
Not yet recruiting
- Non Proliferative Diabetic Retinopathy(NPDR)
- pars plana vitrectomy(PPV)
- +2 more
-
Tianjin, ChinaTianjin medical university eye hospital
May 10, 2023
Congenital Aniridia Patient Questionnaire
Not yet recruiting
- Congenital Aniridia
- Survey
-
Paris, FranceHôpital Necker-Enfants Malades
Jan 16, 2023
Retina Disease, Retinopathy of Prematurity, Ranibizumab Trial in Zagazig (Ranibizumab (0.25 mg/0.025 mL))
Completed
- Retina Disease
- +2 more
- Ranibizumab (0.25 mg/0.025 mL)
-
Zagazig, EgyptZagazig University, Faculty of medicine
Jan 26, 2023
Number of Patient Eyes That Remained on or Switched to Anti-VEGF
Completed
- Age-related Macular Degeneration (AMD)
-
East Hanover, New JerseyNovartis Investigational site
Oct 6, 2021
Neovascular Age-related Macular Degeneration
Completed
- Age-related Macular Degeneration (AMD)
-
East Hanover, New JerseyNovartis Pharmaceuticals
Oct 19, 2021
Corneal Epithelial Wound Trial in Banha, BaNHA (Insulin, autologous serum (AS), conventional)
Not yet recruiting
- Corneal Epithelial Wound
- Insulin
- +2 more
-
Banha, Kalyobeya, Egypt
- +1 more
Apr 15, 2022
Aphakia, Mydriasis Trial in Changzhou (Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage
Recruiting
- Aphakia
- Mydriasis
- Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty
-
Changzhou, Jiangsu, ChinaPreoperatively and 6 Months Postoperatively
Apr 12, 2023
Uveitis, Cystoid Macular Edema Trial in Winston-Salem (Pegaptanib)
Completed
- Uveitis
- Cystoid Macular Edema
-
Winston-Salem, North CarolinaWake Forest University Eye Center
Mar 7, 2022
Iris Color and Day-Night Changes in the Sympathovagal Ratio
Completed
- Iris Diseases
- Iris Color Measurement , LF/HF Measurement
- (no location specified)
Mar 7, 2023
Cortical Porosity in Diabetic Bone Disease
Recruiting
- Type 2 Diabetes
- XtremeCT
-
San Francisco, CaliforniaUniversity of California San Francisco
May 26, 2022
Iris Depigmentation Trial in Sohag (Nd-YAG Laser for iris depigmentation)
Recruiting
- Iris Depigmentation
- Nd-YAG Laser for iris depigmentation
-
Sohag, EgyptElshimaa A.Mateen
Oct 22, 2023
Cataract Trial (IFIS sleeve)
Not yet recruiting
- Cataract
- IFIS sleeve
- (no location specified)
Sep 28, 2023
Feasibility Study and Preliminary Application Study on Iris OCTA
Unknown status
- Conjunctivitis
- +6 more
- OCTA (ZEISS)
- (no location specified)
Sep 5, 2018
Observational Study of Iris Tumors
Recruiting
- Iris Tumor
-
Portland, OregonOregon Health & Science University
Sep 22, 2022
Exudative Retinal Detachment and Uveal Melanoma Trial in Boston (Dexamethasone intravitreal implant)
Recruiting
- Exudative Retinal Detachment and Uveal Melanoma
- Dexamethasone intravitreal implant
-
Boston, Massachusettsi. Ocular Melanoma Center, Massachusetts Eye and Ear
Jul 23, 2021
IRIS- DESyne X2 in the IRIS-DES Registry
Recruiting
- Coronary Stenosis
- +2 more
- DESyne X2
-
Incheon, Korea, Republic of
- +5 more
Dec 11, 2022
Iris Cameras in Mucopolysaccharidoses
Not yet recruiting
- Mucopolysaccharidoses
- Imaging
-
Manchester, United KingdomManchester University NHS Foundation Trust
Aug 30, 2022
Iris Trial in Assiut (Immunohistochemistry analysis)
Not yet recruiting
- Iris
- Immunohistochemistry analysis
-
Assiut, EgyptHassan Lotfy
Jul 29, 2022
Pathologic Myopia Trial in Mykolaiv, Odessa (Intravitreal injection)
Completed
- Pathologic Myopia
- Intravitreal injection
-
Mykolaiv, Ukraine
- +2 more
Jan 23, 2023
Neovascular Age-Related Macular Degeneration Trial in China (Brolucizumab 6mg, Aflibercept 2 mg)
Recruiting
- Neovascular Age-Related Macular Degeneration
- Brolucizumab 6mg
- Aflibercept 2 mg
-
Guangzhou, Guangdong, China
- +30 more
Jan 20, 2023